2',4'-Dimethoxypropiophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2',4'-Dimethoxypropiophenone, also known as 2,4-dimethoxyphenyl propyl ketone, is a synthetic compound that has been studied for its potential therapeutic properties. It has been shown to possess antioxidant, anti-inflammatory, and neuroprotective effects in various experimental models. The compound is typically synthesized through a Friedel-Crafts acylation reaction using 1,3-dimethoxybenzene and propionyl chloride in the presence of a Lewis acid catalyst. Research into 2',4'-Dimethoxypropiophenone has focused on its potential as a treatment for neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. The compound's ability to protect against oxidative stress and inflammation, as well as its interactions with key neurotransmitter systems, have made it a promising target for further investigation.'

Cross-References

ID Source	ID
PubMed CID	70020
CHEBI ID	167433
SCHEMBL ID	4653380

Synonyms (32)

Synonym
CHEBI:167433
1-(2,4-dimethoxyphenyl)propan-1-one
propiophenone, 2',4'-dimethoxy-
1-propanone, 1-(2,4-dimethoxyphenyl)-
nsc34097
2',4'-dimethoxypropiophenone
nsc-34097
831-00-5
IDI1_031024
2',4'-dimethoxypropiophenone, 97%
MAYBRIDGE4_000442
SR-01000633098-1
NCGC00177575-01
HMS1522E02
AKOS000296109
BRD-K60578973-001-01-8
2'.4'-dimethoxypropiophenone
CCG-43153
einecs 212-601-7
nsc 34097
FT-0610147
DTXSID00232167
SCHEMBL4653380
MIAQBCIDZSELDU-UHFFFAOYSA-N
propan-1-one, 1-(2,4-dimethoxyphenyl)-
1-(2,4-dimethoxyphenyl)-1-propanone #
1-(2,4-dimethoxyphenyl)-1-propanone
CS-0204890
9EYJ6T4Z7D
N12069
2'4'-dimethoxypropiophenone 97
BS-22832

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
aromatic ketone	A ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	13.13 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.92 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

chemdatabank.com